Document is current
Any future updates will be listed below
-
Authors
Novruzov, Emil https://orcid.org/0000-0003-1914-1332
Sheikh, Gabriel
Feisthauer, Anna
Schmitt, Dominik
Mattes-György, Katalin
Antke, Christina
Kuhlmann, Julian
Mori, Yuriko
Henke, Jan
Cardinale, Jens
Boschheidgen, Matthias
Radtke, Jan Philipp
Niegisch, Günter
Albers, Peter
Antoch, Gerald
Werner, Rudolf A.
Giesel, Frederik L.
Mamlins, Eduards
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 21 February 2026
First Online: 3 March 2026
<!--Emphasis Type='Bold' removed-->Declarations
:
: All procedures performed in studies involving human participants were approved by the ethics committee and carried out in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study received approval from the Ethical Committee of the Medical Faculty of Heinrich-Heine University Duesseldorf, Germany (Study-Nr.: 2024–2735). Clinical trial number: not applicable.
: Not applicable.
: FLG has patent applications for [ 18 F]PSMA-1007 and is an advisor at ABX, Telix, and SOFIE Biosciences. GN participated in advisory boards of Novartis. The authors have no relevant financial or nonfinancial interests to disclose.
: Informed consent for participation was obtained from all individual participants included in the study, and the investigation was conducted according to national regulatory laws.
